

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96586 A1

(51) International Patent Classification⁷: C12N 15/85,
A61K 48/00, C12Q 1/68, C07H 21/04

(21) International Application Number: PCT/US01/18803

(22) International Filing Date: 11 June 2001 (11.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/593,589 13 June 2000 (13.06.2000) US

(71) Applicant (for all designated States except US): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MONIA, Brett, P.** [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). **BUTLER, Madeline, M.** [US/US]; 15951 Avenida Calma, Rancho Santa Fe, CA 92091 (US). **WYATT, Jacqueline, R.** [US/US]; 1065 Hymettus Avenue, Encinitas, CA 92024 (US).

(74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/96586 A1

(54) Title: ANTISENSE MODULATION OF C/EBP ALPHA EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP alpha. Methods of using these compounds for modulation of C/EBP alpha expression and for treatment of diseases associated with expression of C/EBP alpha are provided.

ANTISENSE MODULATION OF C/EBP ALPHA EXPRESSION

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of C/EBP alpha. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding C/EBP alpha. Such oligonucleotides have been shown to modulate the expression of C/EBP alpha.

BACKGROUND OF THE INVENTION

Transcription factors represent a group of molecules within the cell that function to connect the pathways from extracellular signals to intracellular responses. Immediately after an environmental stimulus, these proteins which reside predominantly in the cytosol are translocated to the nucleus where they bind to specific DNA sequences in the promoter elements of target genes and activate the transcription of these target genes. One family of transcription factors, CCAAT/Enhancer-binding proteins (C/EBPs), regulates the expression of an extensive panel of genes that control normal tissue development and cellular function, cellular proliferation and functional differentiation. Six members of this family have been identified to date all of which form both homo- and heterodimers with other C/EBP family members as well as with members of the NFkB and Fos/Jun families of transcription factors (Lekstrom-Himes and Xanthopoulos, *J. Biol. Chem.*, 1998, 273, 28545-28548). While all of the members of the C/EBP family have a similar modular protein structure, expression levels and tissue distributions vary widely leading to a diversity of roles (Lekstrom-Himes and Xanthopoulos, *J. Biol. Chem.*, 1998, 273, 28545-28548).

The first member, originally isolated from soluble

-2-

extracts of rat liver nuclei, is C/EBP alpha, also known as CEBPA and simply C/EBP (Graves et al., *Cell*, 1986, 44, 565-576; Johnson et al., *Genes Dev.*, 1987, 1, 133-146).

Studies of tissue distribution and developmental expression patterns showed that C/EBP alpha is found primarily in tissues involved in energy metabolism, with a capacity to metabolize lipids, cholesterol and other sterols (Birkenmeier et al., *Genes Dev.*, 1989, 3, 1146-1156). The highest levels of expression were found in the liver, adipose and placental tissue, while lower levels were seen in lung and small intestine.

In studies of the cAMP responsiveness of the phosphoenolpyruvate carboxykinase (PEPCK) gene, Crosson and Roesler designed plasmids that stably express antisense RNA to rat C/EBP alpha or rat C/EBP beta in hepatoma cells (*J. Biol. Chem.*, 2000, 275(8): 5804-5809). Antisense directed against C/EBP alpha mRNA reduced C/EBP alpha protein levels and cAMP responsiveness, while antisense directed against C/EBP beta was without effect.

In studies of the rat, C/EBP alpha has been shown to be involved in the regulation of adipocyte differentiation (Samuelsson et al., *Embo J.*, 1991, 10, 3787-3793; Shao and Lazar, *J. Biol. Chem.*, 1997, 272, 21473-21478). Using vector-directed expression of antisense C/EBP RNA, the authors showed reduced expression of C/EBP alpha transcripts as well as reduced cytoplasmic triglyceride accumulation, indicating the necessity of the alpha isoform in adipocyte differentiation (Lin and Lane, *Genes Dev.*, 1992, 6, 533-544). C/EBP alpha has also been shown to regulate chondrogenic differentiation (Vidal et al., *J. Endocrinol.*, 1997, 155, 433-441), follicular development and ovulation (Piontkewitz et al., *Dev. Biol.*, 1996, 179, 288-296), steroid-induced cell cycle arrest in the liver (Ramos et al., *Mol. Cell. Biol.*, 1996, 16, 5288-5301), and

-3-

controlling GLUT2, a glucose transporter, promotor activity (Kim and Ahn, *Biochem. J.*, 1998, 336, 83-90). It is also expressed in activated microglial cells after brain injury (Walton et al., *Brain Res. Mol. Brain Res.*, 1998, 61, 11-22).

These findings are further supported by studies in humans showing C/EBP alpha to be involved in the hormonal regulation of metabolism and in granulocyte development (Radomska et al., *Mol. Cell. Biol.*, 1998, 18, 4301-4314; Roesler et al., *J. Biol. Chem.*, 1998, 273, 14950-14957).

C/EBP-deficient mice have been generated for five of the six members of the C/EBP family and these have been characterized for system-specific phenotypic abnormalities. C/EBP alpha is the primary signal controlling hepatic terminal differentiation, and mice lacking C/EBP alpha have profound derangement of liver structure and function and the majority die soon after birth due to hypoglycemia. In addition, mice lacking the C/EBP alpha gene exhibit deficient granulopoiesis (Zhang et al., *J. Exp. Med.*, 1998, 188, 1173-1184), liver development (Timchenko et al., *Mol. Cell. Biol.*, 1997, 17, 7353-7361; Tomizawa et al., *Biochem. Biophys. Res. Commun.*, 1998, 249, 1-5) and differentiation of myeloid precursors (Zhang et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 569-574).

In addition to stage-specific expression level variations, the C/EBP members also undergo multiple isoform expression arising from alternative start positions, for the alpha and beta isoforms, in 5' upstream open reading frames (Geballe and Morris, *Trends Biochem. Sci.*, 1994, 19, 159-164; Lincoln et al., *J. Biol. Chem.*, 1998, 273, 9552-9560). The steady-state level of the various pools of transcripts also changes as a function of age and stress challenges (Hsieh et al., *Mol. Biol. Cell*, 1998, 9, 1479-1494). In mice the expression of certain transcripts of

-4-

one isoform has also been shown to regulate the expression of other C/EBP isoforms (Burgess-Beusse et al., *Hepatology*, 1999, 29, 597-601).

C/EBP alpha occurs as two isoforms in the cell, a full-length 42-kDa form and a shorter 30-kDa form. The shorter form displays alternative transactivation potential compared to the full-length protein (Lekstrom-Himes and Xanthopoulos, *J. Biol. Chem.*, 1998, 273, 28545-28548). Disclosed in US Patent 5,545,563 and in the PCT application, WO 94/20113, are the DNA sequence of the entire human C/EBP alpha gene and vectors for its expression (Darlington et al., 1994; Darlington et al., 1996). Also disclosed in WO 94/20113 is the use of the C/EBP alpha gene in methods to treat cancer and other diseases. Antisense agonists of C/EBP alpha are also generally disclosed.

The pharmacological modulation of C/EBP alpha activity and/or expression may therefore be an appropriate point of therapeutic intervention in pathological conditions.

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of C/EBP alpha and to date, investigative strategies aimed at modulating C/EBP alpha function have involved the use of antibodies, antisense expression vectors, and gene knock-outs in mice. However, these strategies are untested as therapeutic protocols and consequently there remains a long felt need for agents capable of effectively inhibiting C/EBP alpha function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of C/EBP alpha expression.

The present invention provides compositions and methods for modulating C/EBP alpha expression, including

-5-

modulation of both the long and short isoforms of C/EBP alpha.

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding C/EBP alpha, and which modulate the expression of C/EBP alpha. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of C/EBP alpha in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of C/EBP alpha by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding C/EBP alpha, ultimately modulating the amount of C/EBP alpha produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding C/EBP alpha. As used herein, the terms "target nucleic acid" and "nucleic acid encoding C/EBP alpha" encompass DNA encoding C/EBP alpha, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to

-6-

it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of C/EBP alpha. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding C/EBP alpha. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the

translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding C/EBP alpha, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a

translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and

therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.

"Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient

-10-

degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted

-11-

oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds

-12-

useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do

-13-

not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are

-14-

retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂- , -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂- , -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA

-15-

cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural"

nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No.

3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base

substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,

-18-

Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantan acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds.

"Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more

chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

-20-

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite

-21-

or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The

free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as

-23-

ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of C/EBP alpha is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense

-24-

compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding C/EBP alpha, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding C/EBP alpha can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of C/EBP alpha in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches,

-25-

ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as,

-26-

but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi *et al.*, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases

-27-

intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be

incorporated into either phase of the emulsion.

Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such

-29-

as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added

-30-

to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component,

-31-

generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, *in: Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, *in Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, *in Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, *in Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol

monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms,

-33-

improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have

-34-

attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As

the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene

to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to

deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising

sphingomyelin. Liposomes comprising 1,2-*sn*-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (Biochimica et Biophysica Acta, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle *et al.* (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*) Liposomes comprising PEG-modified ceramide lipids are described in WO

-39-

96/10391 (Choi *et al.*). U.S. Patent Nos. 5,540,935 (Miyazaki *et al.*) and 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman *et al.* describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties

-40-

of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The

quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the

interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic

-43-

derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycolic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycidihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-

-44-

diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo- alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a

-45-

nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4' isothiocyanostilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen

-46-

phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the

-47-

compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUDR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds.,

-48-

1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅₀s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years.

-49-

Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

-50-

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2 -displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyanyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was

treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a

white solid, mp 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1)

-53-

containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was

-54-

added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5'-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5'-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyl-cytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl (2x300

mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄ and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminoxyethyl) nucleoside amidites

2'- (Dimethylaminoxyethoxy) nucleoside amidites

2'- (Dimethylaminoxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminoxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

-56-

5'-O-tert-Butyldiphenylsilyl- O^2 -2'-anhydro-5-methyluridine

O^2 -2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl- O^2 -2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and

-57-

opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxypthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a

flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminoxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in

-59-

MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

2'-O-(dimethylaminoxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting

- 60 -

material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH_2Cl_2 (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5'-methyluridine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P_2O_5 under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl- $\text{N},\text{N},\text{N}^1,\text{N}^1$ -tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO_3 (40mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminoxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminoxyethyl guanosine analog may be

obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinossio, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxypthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²⁻, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed,

placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the

solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

- 64 -

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*,

-65-

1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me] -- [2'-deoxy] -- [2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The

- 66 -

pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)] -- [2'-deoxy] -- [2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)] -- [2'-deoxy] -- [-2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl) Phosphodiester] -- [2'-deoxy Phosphorothioate] -- [2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl) phosphodiester] -- [2'-deoxy phosphorothioate] -- [2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6**Oligonucleotide Isolation**

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7**Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3, H-1, 2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH₄OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 6 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up

-70-

to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

HepG2 cells:

The human hepatoblastoma cell line HepG2 was obtained from the American Type Culture Collection (Manassas, VA). HepG2 cells were routinely cultured in Eagle's MEM supplemented with 10% fetal calf serum, non-essential amino acids, and 1 mM sodium pyruvate (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

3T3-L1 cells:

The mouse embryonic adipocyte-like cell line 3T3-L1 was obtained from the American Type Culture Collection (Manassas, VA). 3T3-L1 cells were routinely cultured in DMEM, high glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 80% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 4000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

When cells reached 80% confluence, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCC****CCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then

-72-

utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10

Analysis of oligonucleotide inhibition of C/EBP alpha expression

Antisense modulation of C/EBP alpha expression can be assayed in a variety of ways known in the art. For example, C/EBP alpha mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only

-73-

("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

Protein levels of C/EBP alpha can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to C/EBP alpha can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and

-74-

can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for

-75-

cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96TM well plate attached to a QIAVACTM manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96TM plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96TM plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVACTM manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVACTM manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μ L water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of C/EBP alpha mRNA Levels

Quantitation of C/EBP alpha mRNA levels was determined by real-time quantitative PCR using the ABI PRISMTM 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This

-76-

is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems,

-77-

Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMANTM buffer A, 5.5 mM MgCl₂, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLDTM, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLDTM, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Probes and primers to human C/EBP alpha were designed to hybridize to a human C/EBP alpha sequence, using published sequence information (GenBank accession number U34070, incorporated herein as SEQ ID NO:3). For human C/EBP alpha the PCR primers were:

forward primer: TGTGCCCTGGAAATGCAAAC (SEQ ID NO: 4)
reverse primer: CGGGAAGGAGGCAGGAA (SEQ ID NO: 5) and the PCR probe was: FAM-CACCGCTCCAATGCCTACTGAGTAGGG-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR probe was: 5' JOE-CAAGCTTCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Probes and primers to mouse C/EBP alpha were designed to hybridize to a mouse C/EBP alpha sequence, using published sequence information (GenBank accession number M62362, incorporated herein as SEQ ID NO:10). For mouse C/EBP alpha the PCR primers were:

-78-

forward primer: CGCAAGAGCCGAGATAAAGC (SEQ ID NO:11)
reverse primer: CGGTCATTGTCACTGGTCAACT (SEQ ID NO: 12) and
the PCR probe was: FAM-AACGTGGAGACGCAACAGAACAGGTGCT-TAMRA
(SEQ ID NO: 13) where FAM (PE-Applied Biosystems, Foster
City, CA) is the fluorescent reporter dye) and TAMRA (PE-
Applied Biosystems, Foster City, CA) is the quencher dye.
For mouse GAPDH the PCR primers were:

forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO: 14)
reverse primer: GGGTCTCGCTCCTGGAAAGCT (SEQ ID NO: 15) and
the PCR probe was: 5' JOE-AAGGCCGAGAACGGAAAGCTTGTCACTC-
TAMRA 3' (SEQ ID NO: 16) where JOE (PE-Applied Biosystems,
Foster City, CA) is the fluorescent reporter dye) and TAMRA
(PE-Applied Biosystems, Foster City, CA) is the quencher
dye.

Example 14

Northern blot analysis of C/EBP alpha mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then robed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human C/EBP alpha, a human C/EBP alpha specific probe was prepared by PCR using the forward primer

- 79 -

TGTGCCTTGGAAATGCAAAC (SEQ ID NO: 4) and the reverse primer CGGGAAGGAGGCAGGAA (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse C/EBP alpha, a mouse C/EBP alpha specific probe was prepared by PCR using the forward primer CGCAAGAGCCGAGATAAAGC (SEQ ID NO:11) and the reverse primer CGGTCATTGTCACTGGTCAACT (SEQ ID NO: 12). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense inhibition of human C/EBP alpha expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human C/EBP alpha RNA, using published sequences (GenBank accession number U34070, incorporated herein as SEQ ID NO: 3). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The

-80-

internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human C/EBP alpha mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human C/EBP alpha mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID	TARGET NO	SEQUENCE	%INHIB	SEQ ID NO
			SITE			
117325	5'UTR	3	499	cccgaggagaccctgctcgccc	0	17
117326	5'UTR	3	537	ggcggccctccagcctgcgcg	0	18
117327	5'UTR	3	542	gcctcggcggccctccagcct	0	19
117328	5'UTR	3	547	ggcgaggcctcggcggcctcc	0	20
117329	5'UTR	3	552	ggcatggcgagcctcggcgg	0	21
117330	5'UTR	3	557	ctcccgccatggcgagcctc	4	22
117331	5'UTR	3	562	gagttctccggcatggcga	0	23
117332	5'UTR	3	567	agtttagatgtctccggcat	17	24
117333	Start Codon	3	589	aagtccggccgactccatggg	0	25
117334	Start Codon	3	594	cgtagaagtcggccgactcc	48	26
117335	Coding	3	754	gacgtctcgtgctcgagat	0	27
117336	Coding	3	787	gcggccgggtcgatgttaggc	0	28
117337	Coding	3	792	tgaaggcgccgggtcgatg	19	29
117338	Coding	3	797	gtcgttgaaggcggccgggt	38	30
117339	Coding	3	802	aactcgtcgttgaaggcggc	0	31
117340	Coding	3	807	ccaggaactcgtcgttgaag	13	32
117341	Coding	3	812	gtcggccaggaactcgtcgt	51	33
117342	Coding	3	828	ggctgtgctggAACAGGTG	35	34
117343	Coding	3	850	gccttggccttcctcctgt	37	35
117344	Coding	3	997	ctgcgtccaggtagccggc	20	36
117345	Coding	3	1002	ccagcctgcgtccaggtag	39	37
117346	Coding	3	1007	gggctccagcctgcgtcca	11	38
117347	Coding	3	1025	cccgacgcgtcgatcagg	53	39
117348	Coding	3	1030	ggcgccccgacgcgtcgta	0	40
117349	Coding	3	1102	ccggccagcgccagctgtt	0	41
117350	Coding	3	1107	agaggccggccagcgccag	0	42
117351	Coding	3	1208	gtgcgcgtatctgaaactg	27	43
117352	Coding	3	1213	ccgcagtgcgcgtatctgg	37	44
117353	Coding	3	1218	tctggccgcagtgcgcgtc	45	45
117354	Coding	3	1223	ggtggtctggccgcagtgc	0	46
117355	Coding	3	1228	tgcatggtggtctggccgca	0	47
117356	Coding	3	1343	gcccgcccttgagcgccgc	0	48

-81-

117357	Coding	3	1375	ccggccactcgcgccggagggtc	50	49
117358	Coding	3	1414	ttcttgcgtccaccgacttctt	14	50
117359	Coding	3	1419	tgcgttcttgcgtccaccgac	76	51
117360	Coding	3	1428	ggtaactcggtgcgttcttg	75	52
117361	Coding	3	1438	cgcgcgcaccggtaactcggt	69	53
117362	Coding	3	1541	gcggtcattgtcactggtca	0	54
117363	Coding	3	1546	cgcaggcggtcattgtcact	12	55
117364	Coding	3	1551	gcttgcgcaggcggtcattg	69	56
117365	Coding	3	1556	cacccgcgtgcgcaggcggt	10	57
117366	Coding	3	1561	tgttccacccgcgtgcgcag	43	58
117367	Coding	3	1566	tcagctgttccacccgcgtt	82	59
117368	Coding	3	1591	ccccgcagcgtgtccagttc	13	60
117369	Coding	3	1596	agatccccgcagcgtgtcc	48	61
117370	Coding	3	1601	gcggaagatgcggcagcgc	73	62
117371	Coding	3	1606	agctggcggaaagatgcggc	23	63
117372	Coding	3	1630	gccttgaccaaggagctctc	56	64
117373	Coding	3	1635	ccatggcgttgcaccaaggag	36	65
117374	Stop Codon	3	1654	gcgcctcacgcgcagttgcc	64	66
117375	Stop Codon	3	1659	gccgcgcgcctcacgcgcag	40	67
117376	3'UTR	3	1677	gcccaggcggtcccacagc	0	68
117377	3'UTR	3	1715	cgaccgcaccaaccactccctg	2	69
117378	3'UTR	3	1728	cctcgagatccggcgacccc	74	70
117379	3'UTR	3	1735	gggcaaggcgtcgagatccgg	29	71
117380	3'UTR	3	1748	gctcgcacggctcgggcaag	7	72
117381	3'UTR	3	1765	ggaatctcctagtcgtggct	45	73
117382	3'UTR	3	1792	gagcaggccaggcttcagg	0	74
117383	3'UTR	3	1797	acgcggagcaggccaggctt	0	75
117384	3'UTR	3	1802	gggacacgcggagcaggcca	12	76
117385	3'UTR	3	1854	ccgcctggcccccctcatctt	0	77
117386	3'UTR	3	1979	ccctactcgttaggcattgg	86	78
117387	3'UTR	3	2147	acaggcgtggagggagcggct	31	79
117388	3'UTR	3	2324	cccatcgcgtgagttccgc	60	80
117389	3'UTR	3	2337	tcacctggtgaccccccattcg	0	81
117390	3'UTR	3	2376	tagcttctgggtgtactcg	37	82
117391	3'UTR	3	2393	agagctgacccacgacctag	79	83
117392	3'UTR	3	2487	acaaggctgagggtcccagt	45	84
117393	3'UTR	3	2493	gtacaaaacaaggctgagggt	77	85
117394	3'UTR	3	2520	gttccttaggcaatgctgaag	76	86
117395	3'UTR	3	2566	cttgcataactccggtccc	58	87
117396	3'UTR	3	2590	tgataaaagcaaaaatattgg	0	88
117397	3'UTR	3	2611	gataacaagtgttgcatacg	61	89
117398	3'UTR	3	2681	aataaaaatggtggttttagca	0	90
117399	3'UTR	3	2785	cccaaaaaccaaaaaggaaagg	2	91
117400	3'UTR	3	2974	gaaccaaggccgtcccttcct	31	92
117401	3'UTR	3	3018	ataaaaacatctagagtgaga	4	93
117402	3'UTR	3	3039	tttatattatagatataata	6	94

As shown in Table 1, SEQ ID NOS 26, 30, 33, 34, 35, 37, 39, 43, 44, 45, 49, 51, 52, 53, 56, 58, 59, 61, 62, 63, 64, 65, 66, 67, 70, 71, 73, 78, 79, 80, 82, 83, 84, 85, 86, 87, 89 and 92 demonstrated at least 20% inhibition of human C/EBP alpha expression in this assay and are therefore

preferred.

Example 17

Antisense inhibition of mouse C/EBP alpha expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.

In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse C/EBP alpha RNA, using published sequences (GenBank accession number M62362, incorporated herein as SEQ ID NO: 10). The oligonucleotides are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse C/EBP alpha mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

-83-

Table 2

Inhibition of mouse C/EBP alpha mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID
						NO
117326	5'UTR	10	461	ggcggccctccagcctgcgcg	0	18
117327	5'UTR	10	466	gcctccggcgccctccaggct	23	19
117328	5'UTR	10	471	ggcgaggccctccggcgccctc	22	20
117329	5'UTR	10	476	ggcatggcgagcctccggcg	0	21
117330	5'UTR	10	481	ctcccgccatggcgaggcctc	8	22
117331	5'UTR	10	486	gagttctcccgcatggcg	16	23
117332	5'UTR	10	491	agttagagttctcccgcat	1	24
117333	Start Codon	10	513	aagtccggccgactccatggg	18	25
117334	Start Codon	10	518	cgtagaagtcggccgactcc	14	26
117335	Coding	10	678	gacgtctcggtctcgagat	40	27
117336	Coding	10	711	gcggccgggtcgatgttaggc	8	28
117337	Coding	10	716	tgaaggccggccgggtcgatg	0	29
117338	Coding	10	721	gtcggtgaaggccggccgggt	21	30
117339	Coding	10	726	aactcgtcgttgaaggccggc	20	31
117340	Coding	10	731	ccaggaactcgtcgttgaag	1	32
117341	Coding	10	736	gtcgcccaggaaactcgtcgt	16	33
117343	Coding	10	774	gccttggcccttcctcgtcgt	16	35
117344	Coding	10	915	ctgcgtccaggtagccggc	8	36
117345	Coding	10	920	ccagcctgcgtccaggtag	9	37
117346	Coding	10	925	gggctccaggctgcgtcca	22	38
117347	Coding	10	943	cccgacgcgtcgatcagggg	16	39
117348	Coding	10	948	ggcgccccgacgcgtcgta	31	40
117349	Coding	10	1020	ccggccaggcgccaggctgtt	12	41
117350	Coding	10	1025	agaggccggccaggcgccagc	14	42
117351	Coding	10	1120	gtgcgcgtatctgaactgca	49	43
117352	Coding	10	1125	ccgcagtgcgcgtatctggaa	37	44
117353	Coding	10	1130	tctggccgcagtgcgcgatc	10	45
117354	Coding	10	1135	ggtgtctggccgcagtgcg	0	46
117355	Coding	10	1140	tgcattgggtctggccgca	2	47
117358	Coding	10	1341	ttcttgtccaccgacttctt	0	50
117359	Coding	10	1346	tgctgttcttgtccaccgac	37	51
117360	Coding	10	1355	ggtaactcggtgtctgttctt	27	52
117362	Coding	10	1468	gcggtcattgtcactggtca	44	54
117363	Coding	10	1473	cgcaggcggtcattgtcact	19	55
117364	Coding	10	1478	gcttgcgcaggcggtcattg	0	56
117365	Coding	10	1483	cacccgcttgcgcaggcggt	0	57
117366	Coding	10	1488	tgttccaccgcgttgcgcag	22	58
117367	Coding	10	1493	tcagctgttccaccgcgtt	0	59
117368	Coding	10	1518	ccccgcagcgtgtccagttc	39	60
117369	Coding	10	1523	agatccccgcagcgtgtcc	10	61
117370	Coding	10	1528	gcggaagatccccgcagcg	29	62
117371	Coding	10	1533	agctggcggaagatccccg	22	63
117372	Coding	10	1557	gccttgaccaaggagctctc	17	64
117373	Coding	10	1562	ccatggccttgaccaaggag	31	65
117374	Coding	10	1580	gcgcctcacgcgcagttgcc	19	66

- 84 -

117375	Coding	10	1585	gccgcgcgcctcacgcgcag	16	67
117381	Stop	10	1692	ggaatctccttagtcctggct	35	73
	Codon					
117382	3'UTR	10	1719	gagcaggccaggcgttcagg	1	74
117383	3'UTR	10	1724	acgcggaggcaggccaggcct	12	75
117384	3'UTR	10	1729	gggacacgcggagcaggcca	10	76
117396	3'UTR	10	2474	tgataaagcaaaatattgg	0	88
117397	3'UTR	10	2495	gatacaagtgttgatatcgg	16	89
117398	3'UTR	10	2565	aataaaatggtggttagca	0	90
117402	3'UTR	10	2990	tttatattatagatataata	24	94

As shown in Table 2, SEQ ID NOS 19, 20, 27, 30, 38, 40, 43, 44, 51, 52, 54, 58, 60, 62, 63, 65, 73 and 94 demonstrated at least 20% inhibition of mouse C/EBP alpha expression in this experiment and are therefore preferred.

Example 18

Western blot analysis of C/EBP alpha protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to C/EBP alpha is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding C/EBP alpha, wherein said antisense compound specifically hybridizes with and inhibits the expression of C/EBP alpha.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 19, 20, 26, 27, 30, 33, 34, 35, 37, 38, 39, 40, 43, 44, 45, 49, 51, 52, 53, 54, 56, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 70, 71, 73, 78, 79, 80, 82, 83, 84, 85, 86, 87, 89, 92 or 94.
4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically

-86-

acceptable carrier or diluent.

12. The pharmaceutical composition of claim 11 further comprising a colloidal dispersion system.

13. The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of C/EBP alpha in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of C/EBP alpha is inhibited.

15. A method of treating an animal having a disease or condition associated with C/EBP alpha comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of C/EBP alpha is inhibited.

16. The method of claim 15 wherein the disease or condition is a developmental disorder.

17. The method of claim 15 wherein the disease or condition is diabetes.

18. The method of claim 15 wherein the disease or condition is an hepatic disorder.

19. The method of claim 15 wherein the disease or condition is obesity.

20. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

SEQUENCE LISTING

<110> Brett P. Monia
Madeline M. Butler
Jacqueline Wyatt
Isis Pharmaceuticals, Inc.

<120> ANTISENSE MODULATION OF C/EBP ALPHA EXPRESSION

<130> RTSP-0151

<150> 09/953,589
<151> 2000-06-13

<160> 94

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 1
tccgtcatcg ctcctcaggg

20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 2
atgcattctg cccccaagga

20

<210> 3
<211> 3318
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (592) ... (1668)

<400> 3
ctgcagcctc cccgggacgc gggtccggga caggcctggc tctggctttg aaagagaatc 60
cgcgccccag cagctcaaga ccaagactcg ccctccgccc cccaccccta ccccggtgcag 120
cctcggata ctccctggct cccggccgtg gctggatacg ggccgcctagg gcaggcagga 180
ggagggggcc cccgctacccg accacgtggg cgccggggcg acggccgggc cggggggcgga 240
gcttggagcg agcgccgcgg ctctgctggg cgccgtggag gcgggtggcg ttgcgcggcg 300
gcctgcctgg ggagcgcggc gctgtgccgc gtggttcgcc gccccatgcc ggccgcgcgc 360
taggacccag caggcgcgcgc gccgcgcgcag cccggggaca gaggccgcct cggactctag 420
ggggcgcacgc ggcctgcggg gtataaaagc tgggcccggcg cggccgggc cattcgcgcac 480
ccggaggtgc gcgggcgcgg gcgagcaggg tctccgggtg ggccggcggcg acgccccgcg 540

caggctggag	gccggcgagg	ctcgccatgc	cgggagaact	ctaaactcccc	c	atg	gag	597									
					atg	Met	Glu										
						1											
tcg	gcc	gac	ttc	tac	gag	gcg	gag	597									
Ser	Ala	Asp	Phe	Tyr	Ala	Glu	Pro	Arg	Pro	Pro	Met	Ser	Ser	His	645		
5					10							15					
ctg	cag	agc	ccc	ccg	cac	gcg	ccc	agc	agc	gcc	gcc	ttc	ggc	ttt	ccc	693	
Leu	Gln	Ser	Pro	Pro	His	Ala	Pro	Ser	Ser	Ala	Ala	Phe	Gly	Phe	Pro		
20					25							30					
cgg	ggc	gag	ggc	ccg	ccg	aag	cct	ccc	gcc	cca	cct	gcc	gcc	ccg	gag	741	
Arg	Gly	Ala	Gly	Pro	Pro	Lys	Pro	Pro	Ala	Pro	Pro	Pro	Ala	Ala	Pro	Glu	
35					40							45			50		
ccg	ctg	ggc	ggc	atc	tgc	gag	cac	gag	acg	tcc	atc	gac	atc	agc	gcc	789	
Pro	Leu	Gly	Gly	Ile	Cys	Glu	His	Glu	Thr	Ser	Ile	Asp	Ile	Ser	Ala		
55					60							65					
tac	atc	gac	ccg	gcc	gcc	ttc	aat	gac	gag	ttc	ctg	gcc	gac	ctg	ttc	837	
Tyr	Ile	Asp	Pro	Ala	Ala	Phe	Asn	Asp	Glu	Phe	Leu	Ala	Asp	Leu	Phe		
70					75							80					
cag	cac	agc	ccg	cag	cag	gag	aag	gcc	aag	gcg	gcc	gtg	ggc	ccc	acg	885	
Gln	Ser	Arg	Gln	Gln	Glu	Lys	Ala	Lys	Ala	Ala	Val	Gly	Pro	Thr			
85					90							95					
ggc	ggc	ggc	ggc	ggc	gac	ttt	gac	tac	ccg	ggc	gag	ccc	ccg	ggc	933		
Gly	Gly	Gly	Gly	Gly	Asp	Phe	Asp	Tyr	Pro	Gly	Ala	Pro	Ala	Gly			
100					105							110					
ccc	ggc	ggc	gcc	gtc	atg	ccc	ggg	gga	gcg	cac	ggg	ccc	ccg	ccc	ggc	981	
Pro	Gly	Gly	Ala	Val	Met	Pro	Gly	Gly	Ala	His	Gly	Pro	Pro	Pro	Gly		
115					120							125			130		
tac	ggc	tgc	gag	gcc	gcc	ttc	tac	ctg	gac	ggc	agg	ctg	gag	ccc	ctg	1029	
Tyr	Gly	Cys	Ala	Ala	Gly	Tyr	Leu	Asp	Gly	Arg	Leu	Glu	Pro	Leu			
135					140							145					
tac	gag	ccg	gtc	ggg	gag	ccg	gag	ctg	ccg	ctg	gtg	atc	aag	cag	1077		
Tyr	Glu	Arg	Val	Gly	Ala	Pro	Ala	Leu	Arg	Pro	Leu	Val	Ile	Lys	Gln		
150					155							160					
gag	ccc	ccg	gag	gag	gat	gaa	gcc	aag	cag	ctg	gag	ctg	gcc	ggc	ctc	1125	
Glu	Pro	Arg	Glu	Glu	Asp	Glu	Ala	Lys	Gln	Leu	Ala	Leu	Ala	Gly	Leu		
165					170							175					
ttc	cct	tac	cag	ccg	ccg	ccg	ccg	ccg	ccc	tcg	cac	ccg	cac	ccg	1173		
Phe	Pro	Tyr	Gln	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Ser	His	Pro	His	Pro		
180					185							190					
cac	ccg	ccg	ccc	gag	cac	ctg	gcc	ccg	cac	ctg	cag	ttc	cag	atc	1221		
His	Pro	Pro	Pro	Ala	His	Leu	Ala	Ala	Pro	His	Leu	Gln	Phe	Gln	Ile		
195					200							205			210		
gcg	cac	tgc	ggc	cag	acc	acc	atg	cac	ctg	cag	ccc	ggt	cac	ccc	acg	1269	
Ala	His	Cys	Gly	Gln	Thr	Thr	Met	His	Leu	Gln	Pro	Gly	His	Pro	Thr		
215					220							225					
ccg	ccg	ccc	acg	ccc	gtg	ccc	agc	ccg	cac	ccc	gag	ccc	gag	ctc	1317		
Pro	Pro	Pro	Thr	Pro	Val	Pro	Ser	Pro	His	Pro	Ala	Pro	Leu	Gly			
230					235							240					
gcc	gcc	ggc	ctg	ccg	ggc	cct	ggc	agc	gag	ctc	aag	ggg	ctg	ggc	gcc	1365	
Ala	Ala	Gly	Leu	Pro	Gly	Ser	Ala	Leu	Lys	Gly	Leu	Gly	Leu	Gly	Ala		

tccttttgtt tttgggatata ctttgatcc tgggggacca atgaggttag gggggttctc 2848
 ctttgccttc agcttcccc agccctccg gcctggctg cccacaaggc ttgtccccca 2908
 gaggccctgg ctccctggctg ggaaggagg tggcctcccg ccaacgcatac actggggctg 2968
 ggagcaggga aggacggctt gggtctcttc ttttggggag aacgttagat ctcactctag 3028
 atgtttatg tattatatct ataataaaaa catatcaaag tcaatgtcgg tgtctttta 3088
 aaaccagaaa gaagctactt ccaagggtgt ctgtggcca ggtcacatggtaaataata 3148
 cagcattttc cctggggca atcctgactt tcatgagctc tccatccatc ctgagccct 3208
 cttaccctaa ggggtgact tacttccccca aggcaagaca aataaatagc agaggacaag 3268
 gctccaaatg gagtatgtcc agagcctgaa ggcagtcctc tggcgtcagg 3318

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 4
 tgtgccttgg aaatgcaaac

20

<210> 5
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 5
 cgggaaggag gcagggaa

17

<210> 6
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 6
 caccgctcca atgcctactg agtaggg

27

<210> 7
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 7
 gaaggtgaag gtcggagtc

19

<210> 8
 <211> 20
 <212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 8

gaagatggtg atgggatttc

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 9

caagcttccc gttctcagcc

20

<210> 10

<211> 3023

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (516) . . . (1703)

<400> 10

acgctcccca acctccaccc cccctcgctc ggccctctata tgctcccggg ctccctagtg 60

ttggctggaa gtgggtgact tagaggctta aaggaggggc gcctaaccac ggaccacgtg 120

tgtgcggggg cgacagcgcc gccgggggtgg ggctgagcgc tgcaagccgg gttcgcccttg 180

cagcgcagga gtcagtgggc gttgcgccac gatctctctc cactagcact atgctcccg 240

cccactcacc gccttggaaa gtcacaggag aaggcgggct ctaagaccca gcaggcacca 300

tcctactggc gccttcgatc cgagaccgt ttggacacca gggggcgatg ccgaccctct 360

ataaaagcgg tccccgcgcg ggcctggcca ttgcgcaccc gaagctgcgc gggcgcgagc 420

cagttggggc actgggtggg cggcggcgac agcggcgcac cgccgaggct ggaggccgccc 480

gaggctcgcc atgccgggag aactctaact ccccc atg gag tcg gcc gac ttc 533
Met Glu Ser Ala Asp Phe

1

5

tac gag gtg gag ccg cgg ccc ccg atg agc agt cac ctc cag agc ccc 581
Tyr Glu Val Glu Pro Arg Pro Pro Met Ser Ser His Leu Gln Ser Pro
10 15 20ccg cac gcg ccc agc aac gcc cgc ctt tgg ctt tcc ccg ggg cgc ggg 629
Pro His Ala Pro Ser Asn Ala Arg Leu Trp Leu Ser Pro Gly Arg Gly
25 30 35ccc cgc gcc gcc ccc agc ccc acc tgc cgc ccc gga gcc gct ggg cgg 677
Pro Arg Ala Ala Pro Ser Pro Thr Cys Arg Pro Gly Ala Ala Gly Arg
40 45 50atc tgc gag cac gag acg tct ata gac atc agc gcc tac atc gac ccg 725
Ile Cys Glu His Glu Thr Ser Ile Asp Ile Ser Ala Tyr Ile Asp Pro
55 60 65 70

gcc gcc ttc aac gac gag ttc ctg gcc gac ctc ttc cag cac agc cga 773

Ala	Ala	Phe	Asn	Asp	Glu	Phe	Leu	Ala	Asp	Leu	Phe	Gln	His	Ser	Arg		
					75				80				85				
cag	cag	gag	aag	gcc	aag	gct	gct	gct	ccc	gct	ggt	ggc	ggc	ggt		821	
Gln	Gln	Glu	Lys	Ala	Lys	Ala	Ala	Gly	Pro	Ala	Gly	Gly	Gly	Gly			
					90				95				100				
gac	ttt	gac	tac	ccg	gga	gcc	ccg	gct	ccc	ggc	ggc	gct	atg			869	
Asp		Phe	Asp	Tyr	Pro	Gly	Ala	Pro	Ala	Gly	Pro	Gly	Gly	Ala	Val	Met	
					105				110				115				
tcc	gct	ggg	gct	cac	ggg	ccc	cct	ccc	ggc	tac	ggc	tgt	gct	gct		917	
Ser	Ala	Gly	Ala	His	Gly	Pro	Pro	Pro	Gly	Tyr	Gly	Cys	Ala	Ala			
					120				125				130				
ggc	tac	ctg	gac	ggc	agg	ctg	gag	ccc	ctg	tac	gag	cg	gtc	ggg	gct	965	
Gly	Tyr	Leu	Asp	Gly	Arg	Leu	Glu	Pro	Leu	Tyr	Glu	Arg	Val	Gly	Ala		
					135				140				145			150	
ccc	gct	cta	cg	ccg	ctg	gt	atc	aaa	caa	gag	ccc	cg	gag	gag	gac	1013	
Pro	Ala	Leu	Arg	Pro	Leu	Val	Ile	Lys	Gln	Glu	Pro	Arg	Glu	Glu	Asp		
					155				160				165				
gag	gct	aag	cag	ctg	gct	ctg	gct	ccc	tac	cag	cca	ccg				1061	
Glu	Ala	Lys	Gln	Leu	Ala	Leu	Ala	Gly	Leu	Phe	Pro	Tyr	Gln	Pro	Pro		
					170				175				180				
ccg	cca	ccg	cca	ccg	ccg	cac	ccg	cac	gct	tct	ccc	gct	cac	ctg	gcc	1109	
Pro	Pro	Pro	Pro	Pro	Pro	His	Pro	His	Pro	His	Ala	Ser	Pro	Ala	His	Leu	Ala
						185				190				195			
gcc	ccc	cac	ttg	cag	ttc	cag	atc	gct	cac	tgc	ggc	cag	acc	acc	atg	1157	
Ala	Pro	His	Leu	Gln	Phe	Gln	Ile	Ala	His	Cys	Gly	Gln	Thr	Thr	Met		
					200				205				210				
cac	cta	cag	cct	ggc	cac	ccc	aca	ccg	ccg	ccc	acg	ccc	gt	ccc	agc	1205	
His	Leu	Gln	Pro	Gly	His	Pro	Thr	Pro	Pro	Pro	Thr	Pro	Val	Pro	Ser		
					215				220				225			230	
ccg	cac	gct	gct	ccc	gcc	ttg	ggt	gct	gct	ggc	ctg	cct	ggc	ccc	gg	1253	
Pro	His	Ala	Ala	Pro	Ala	Leu	Gly	Ala	Ala	Gly	Leu	Pro	Gly	Pro	Gly		
					235				240				245				
agc	gct	ctc	aag	ggc	ttg	gct	gct	ccc	gac	ctc	cg	ac	gg			1301	
Ser	Ala	Leu	Lys	Gly	Leu	Ala	Gly	Ala	His	Pro	Asp	Leu	Arg	Thr	Gly		
					250				255				260				
ggc	ggc	ggc	ggc	agc	gg	gg	gg	gg	gg	aaa	ggc	aag	aag	tcg		1349	
Gly	Gly	Gly	Gly	Ser	Gly	Ala	Gly	Ala	Gly	Aia	Gly	Lys	Ala	Lys	Lys	Ser	
					265				270				275				
gt	gac	aag	aa	agc	aa	gag	tac	cg	cg	cg	gaa	cg	aa	ac	ac	1397	
Val	Asp	Lys	Asn	Ser	Asn	Glu	Tyr	Arg	Val	Arg	Arg	Glu	Arg	Asn	Asn		
					280				285				290				
atc	gct	gt	cg	aag	agc	cg	gat	aaa	ggc	aaa	caa	cg	aa	cg	aa	1445	
Ile	Ala	Val	Arg	Lys	Ser	Arg	Asp	Lys	Ala	Lys	Gln	Arg	Asn	Val	Glu		
					295				300				305			310	
acg	caa	cag	aag	gt	ctg	gag	ttg	acc	agt	gac	aat	gac	cg	ctg	cg	1493	
Thr	Gln	Gln	Lys	Val	Leu	Glu	Leu	Thr	Ser	Asp	Asn	Asp	Arg	Leu	Arg		
					315				320				325				
aag	cg	gt	gaa	cag	ctg	agc	cgt	gaa	ctg	gac	acg	ctg	cg	gg	atc	1541	
Lys	Arg	Val	Glu	Gln	Leu	Ser	Arg	Glu	Leu	Asp	Thr	Leu	Arg	Gly	Ile		
					330				335				340				

ttc cgc cag ctg cct gag agc tcc ttg gtc aag gcc atg gca act gcg	1589		
Phe Arg Gln Leu Pro Glu Ser Ser Leu Val Lys Ala Met Ala Thr Ala			
345	350	355	
cgt gag gcg cgc ggc tgc ggg acc gcc ttg ggc cgg ccc cct ggc tgg	1637		
Arg Glu Ala Arg Gly Cys Gly Thr Ala Leu Gly Arg Pro Pro Gly Trp			
360	365	370	
aga ccc aga gga tgg ttt cgg gtc gct gga tct cta ggc tgc ccc ggc	1685		
Arg Pro Arg Gly Trp Phe Arg Val Ala Gly Ser Leu Gly Cys Pro Gly			
375	380	385	390
cgc gca agc cag gac tag gagattccgg tgtggcctga aagcctggcc tgctccgagt	1743		
Arg Ala Ser Gln Asp			
395			
gtccccatccc ttccctctgag ccggactcg cgctcgatctaa atgagggagt caggccgtgg	1803		
tggtttctcc ttgagaccga gagactttc cgccggagctg agctgggggc ccggcactac	1863		
tagtattaag gaagtaacct tgtgccttgg atactcaaaa ctgcgtcctt ttccctaccga	1923		
gtagggggag caaaaatgtg ccttgcattt ttatggag gattcctgtct tcctctcggg	1983		
cctcagctgg ccccccgtgag aaaaatgaag ggtgcaggcc cagggcagga ggaagataca	2043		
ggaagctgag atcccgccag tgccctgago tgccctcag tccctgtctt tagagggag	2103		
ggacttaggt gttgggatt ttagtctgtg tcctcaccc cagctacagg gaggtggagg	2163		
gctcctaatac cttgccttt tgacacccca cttacatccc cccccccca ctcaatcc	2223		
aacaggccag gttccctggg ttagttcatg gagaatgggg gcaccacccc cagtcagaca	2283		
gaaagctgag ttgtgagttt gccatgtggt aggagacaga gacctaggtt tctggcttt	2343		
gtgggggtggg ggataggagg acacggggac cattagcctt gtgtgtactg tatgtcgcca	2403		
gccgcgtttt ctgaaggAAC ttgaaggACA atcgatccat cccagaggGA ctggagttat	2463		
gacaagcttc ccaaataatTT tgctttatca tccgatataca acacttgtat ctggctctg	2523		
tgtccctgtcg gtgcctgtg caatggcagt gtgcacgtct atgctaaacc accatTTT	2583		
ttggtagttt gttttgtttt ggtttgctc tgattttgc caaaactgaga ctcttcacta	2643		
acggctgggg gaaggagctg agtggggctc tcatttttt tggttaggg atgtttgggt	2703		
tttttcgtct gcctccaga ggaccaatga aatgaagtgg gcttccccct ctccctagt	2763		
tgtccaaggAG tggatgttagt agtgggtctt agcttcctcc ggctaaagact taggcttccc	2823		
cacccaccca accccatccc caacggccct ggctctgggt ctggaaagaa ggccacctcc	2883		
agccagttca tacacacacc cctgtggctg ggagcaggGC tggaccgctt cttcttttcc	2943		
ttttttggg gggggggaca caaagttca tgctagatgt cgtatgtatt atatctataa	3003		
tataaacata tcaaactcaa	3023		

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 11

cgcaagagcc gagataaagc

20

<210> 12

<211> 22

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 12

cggtcattgt cactggcaa ct

22

<210> 13

<211> 26

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 13

aacgtggaga cgcaacagaa ggtgct

26

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 14

ggcaaattca acggcacagt

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 15

gggtctcgct cctggaagct

20

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 16

aaggccgaga atgggaagct tgtcatc

27

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 17

cccgaggacc ctgctcgccc

20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 18

ggcggccctcc agcctgcgcg

20

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19

gcctcggcgg cctccagcct

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20

ggcgaggccctc ggccggccctcc

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21

ggcatggcga gcctcggcgg

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22

ctcccgccat ggcgaggccctc

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23

gagttctccc ggcattggcga

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24

agtttagagtt ctcccgccat

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25

aagtcggccg actccatggg

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26

cgtagaagtc ggccgactcc

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27

gacgtctcgt gctcgcagat

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28

gccccccgggt cgatgttaggc

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29

tgaaggcggc cgggtcgatg

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30

gtcggttgaag gcggccgggt

20

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31

aactcgtcgt tgaaggcggc

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32

ccaggaactc gtcgttgaag

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33

gtcggccagg aactcgtcgt

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34

ggctgtgctg gaacaggctcg

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35

gccttggcct tctcctgctg

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36

ctgccgtcca ggttagccggc

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37

ccagcctgcc ctccaggtag

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38

gggctccagc ctgccgtcca

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39

cccgacgcgc tcgtacaggg

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40

ggcgccccga cgcgctcgta

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41

ccggccagcg ccagctgctt

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42

agaggccggc cagcgccagc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43

gtgcgcgatc tggaaactgca

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44

ccgcagtgcg cgatctggaa

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45

tctggccgca gtgcgcgatc

20

<210> 46

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46

ggtgtctgg ccgcagtgcg

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47

tgcatggtgg tctggccgca

20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 48

gccccagcccc ttgagcgcgc

20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 49

ccgcccactcg cgcgagggtc

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 50

tttttgtcca ccgacttctt

20

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 51

tgcgttctt gtccaccgac

20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 52

ggtaactcggtt gctgttcttg

20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 53

cgccgcaccc ggtactcgtt

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 54

gcggtcattg tcactggtca

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 55

cgcaggcggt cattgtcact

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 56

gcttgcgca gcggtcattg

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 57

cacccgcattg cgcaaggcggt

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 58

tgtccaccc gcttgcgca

20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 59

tcagctgttc caccggatgg

20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 60

ccccgcagcg tgtccagttc

20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 61

agatgccccg cagcgtgtcc

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 62

gcggaagatg ccccgcaagcg

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 63

agctggcgga agatgccccg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 64

gccttgacca aggagctctc

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 65

ccatggcctt gaccaaggag

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 66

gcgcctcacg cgcagttgcc

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 67

gcgcgcgcgc tcacgcgcag

20

<210> 68

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 68

gcccgaggcg gtcccacacgc

20

<210> 69

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 69

cgaccccaaa ccactccctg

20

<210> 70

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 70

cctcgagatc cggcgacccc

20

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 71

gggcaaggctt cgagatccgg

20

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 72

gctcgcacgg ctcgggcaag

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 73

ggaatctcctt agtcctggct

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 74

gagcaggcca ggctttcagg

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 75

acgcggagca ggccaggctt

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 76

gggacacgcg gagcaggcca

20

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 77

ccgcctggcc ccctcatctt

20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 78

ccctactcag taggcattgg

20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 79

acagggcgtgg aggagcggct

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 80

cccatcgcag tgagttccgc

20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 81

tcacacctgtg acccccatcg

20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 82

tagctttctg gtgtgactcg

20

<210> 83

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 83

agagctgacc cacgacccatg

20

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 84

acaaggctga gggtcccagt

20

<210> 85

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 85

gtacaaacaa ggctgagggt

20

<210> 86

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 86

gttccttaggc aatgctgaag

20

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 87

cttgcataa ctccgggtccc

20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 88

tgataaagca aaatatttgg

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 89

gatacaaggatg ttgatatacg

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 90

aataaaatgg tggtttagca

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 91

cccaaaaccca aaaggaaagg

20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 92

gaacccaagcc gtccttcct

20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 93

ataaaaacatc tagagtgaga

20

<210> 94

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 94

tttatattat agatataata

20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/18803

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C12N 15/85; A61K 48/00; C12Q 1/68; C07H 21/04
US CL :435/6; 536/23.1, 24.1, 24.5; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 536/23.1, 24.1, 24.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NoneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, CAPLU, MEDLINE, EMBASE, BIOTECHNO

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,801,154 A (BARACCHINI et al) 01 September 1998, see entire document.	1, 2, 4-14 -----
---		3, 15-20
A		
Y	CROSSON et al. Hormonal Regulation of the Phosphoenolpyruvate Carboxykinase Gene. The Journal of Biological Chemistry. 25 February 2000. Vol. 275, No. 8, pages 5804-5809, see entire document.	1, 2, 4-14 -----
---		3, 15-20
A		

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
25 JULY 2001	18 OCT 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer SEAN MCGARRY 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196